New cholesterol guidelines not 'one size fits all'

January 14, 2002

DALLAS, - A new study advises physicians to fully understand the expanded benefits of the new cholesterol guidelines, citing that the new recommendations are likely to significantly raise the number of people under 45 and older than 65 who are prescribed cholesterol-lowering medications, according to a report in today's Circulation: Journal of the American Heart Association.

The authors say that while there are trials to determine the benefit of cholesterol lowering in elderly populations, no formal studies are ongoing for younger patients. "The ability to generalize the primary prevention trial results, particularly to younger patients, must be explored," according to the paper.

"The health policy implications of the guidelines should be considered and addressed along with their adoption," says Donald O. Fedder, Ph.D., lead author of the study that examines the implications of the NCEP III guidelines on different population groups. "The new guidelines have increased the number of people eligible for drug treatment."

According to National Cholesterol Education Program (NCEP) III guidelines published in 2001, people at higher risk for heart disease with LDL cholesterol levels (the "bad" cholesterol) of 130mg/dL or greater are eligible for cholesterol-lowering treatment. This replaced the NCEP II guidelines set in 1993, which set LDL levels of 160mg/dL or higher as the treatment-eligible criteria for the same individuals.

"We're saying that there needs to be some caution," says Fedder, who is professor of pharmacy and medicine at University of Maryland, Baltimore. "My concern is over-treatment, or that doctors will interpret the findings to mean that everybody needs to be treated to a level below 100 mg/dL. We must make certain that clinicians are instructed in the proper use of the guidelines."

Researchers took a sample of people ages 20 to 79 years old from the third annual National Health and Nutrition Survey. They identified 13,589 people with known cardiovascular risk factors and LDL levels. Researchers then assessed the participants' eligibility for drug therapy first using NCEP II guidelines (160mg/dL) and then the new NCEP III criteria (130mg/dL).

According to the study, a projected 15 million people ages 20 to 79 would be eligible for drug therapy under NCEP II guidelines. Of these, 51 percent were male and 49 percent female; 26 percent were younger than age 45 and 28 percent were 65 years or older. Under the new NCEP III guidelines, 36 million are treatment eligible; of these 55 percent are male and 45 percent female; 32 percent are younger than 56 and 27 percent are 65 or older. This represents a 140 percent increase in eligibility overall.

The new recommendations also alter the gender distribution of treatment-eligible patients - the number of women eligible for treatment increases 122 percent (from 7 to 16 million), while the number of treatment-eligible men increases 157 percent (from 8 to 20 million).

In looking at age distribution, the new guidelines incur a 131 percent increase among those 65 or older (from 4 to 10 million) and a 201 percent increase among those younger than 45 (from 4 to 12 million). Of those deemed eligible for treatment, 26 percent of males and 24 percent of females, 39 percent of those older than 65 and 14 percent of those younger than 45 would be targeted for LDL lowering to less than 100 mg/dL.

The study also raises other issues. Under NCEP II, treatment was indicated in roughly equal numbers of males and females; whereas under NCEP III, proportionally more men than women are eligible. "Although these differences in risk are factual, this runs counter to the current opinion that cardiovascular risk should be regarded as equally relevant in females and males," according ot the study. Sidney Smith, M.D., chief science officer for the American Heart Association, says,

"The important message is that under the new guidelines, many more patients will benefit from cholesterol lowering therapy because their need for therapy is based on their individual risk of heart disease. It's also important to remember that diet and exercise also lower cholesterol and are a valuable part of all treatment strategies."
-end-
Co-authors are Carol E. Koro, M.D. and Gilbert J. L'Italien, M.D.

CONTACT: For journal copies only, please call: 214-706-1396
For other information, call: Carole Bullock: 214-706-1279 or Maggie Francis: 214-706-1397

American Heart Association

Related Heart Disease Articles from Brightsurf:

Cellular pathway of genetic heart disease similar to neurodegenerative disease
Research on a genetic heart disease has uncovered a new and unexpected mechanism for heart failure.

Mechanism linking gum disease to heart disease, other inflammatory conditions discovered
The link between periodontal (gum) disease and other inflammatory conditions such as heart disease and diabetes has long been established, but the mechanism behind that association has, until now, remained a mystery.

New 'atlas' of human heart cells first step toward precision treatments for heart disease
Scientists have for the first time documented all of the different cell types and genes expressed in the healthy human heart, in research published in the journal Nature.

With a heavy heart: How men and women develop heart disease differently
A new study by researchers from McGill University has uncovered that minerals causing aortic heart valve blockage in men and women are different, a discovery that could change how heart disease is diagnosed and treated.

Heart-healthy diets are naturally low in dietary cholesterol and can help to reduce the risk of heart disease and stroke
Eating a heart-healthy dietary pattern rich in vegetables, fruits, whole grains, low-fat dairy products, poultry, fish, legumes, vegetable oils and nuts, which is also limits salt, red and processed meats, refined-carbohydrates and added sugars, is relatively low in dietary cholesterol and supports healthy levels of artery-clogging LDL cholesterol.

Pacemakers can improve heart function in patients with chemotherapy-induced heart disease
Research has shown that treating chemotherapy-induced cardiomyopathy with commercially available cardiac resynchronization therapy (CRT) delivered through a surgically implanted defibrillator or pacemaker can significantly improve patient outcomes.

Arsenic in drinking water may change heart structure raising risk of heart disease
Drinking water that is contaminated with arsenic may lead to thickening of the heart's main pumping chamber in young adults, according to a new study by researchers at Columbia University Mailman School of Public Health.

New health calculator can help predict heart disease risk, estimate heart age
A new online health calculator can help people determine their risk of heart disease, as well as their heart age, accounting for sociodemographic factors such as ethnicity, sense of belonging and education, as well as health status and lifestyle behaviors.

Wide variation in rate of death between VA hospitals for patients with heart disease, heart failure
Death rates for veterans with ischemic heart disease and chronic heart failure varied widely across the Veterans Affairs (VA) health care system from 2010 to 2014, which could suggest differences in the quality of cardiovascular health care provided by VA medical centers.

Heart failure: The Alzheimer's disease of the heart?
Similar to how protein clumps build up in the brain in people with some neurodegenerative diseases such as Alzheimer's and Parkinson's diseases, protein clumps appear to accumulate in the diseased hearts of mice and people with heart failure, according to a team led by Johns Hopkins University researchers.

Read More: Heart Disease News and Heart Disease Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.